Nature Communications (Jun 2021)
Molecular determinants of response to PD-L1 blockade across tumor types
- Romain Banchereau,
- Ning Leng,
- Oliver Zill,
- Ethan Sokol,
- Gengbo Liu,
- Dean Pavlick,
- Sophia Maund,
- Li-Fen Liu,
- Edward Kadel,
- Nicole Baldwin,
- Suchit Jhunjhunwala,
- Dorothee Nickles,
- Zoe June Assaf,
- Daniel Bower,
- Namrata Patil,
- Mark McCleland,
- David Shames,
- Luciana Molinero,
- Mahrukh Huseni,
- Shomyseh Sanjabi,
- Craig Cummings,
- Ira Mellman,
- Sanjeev Mariathasan,
- Priti Hegde,
- Thomas Powles
Affiliations
- Romain Banchereau
- Genentech
- Ning Leng
- Genentech
- Oliver Zill
- Genentech
- Ethan Sokol
- Foundation Medicine
- Gengbo Liu
- Genentech
- Dean Pavlick
- Foundation Medicine
- Sophia Maund
- Genentech
- Li-Fen Liu
- Genentech
- Edward Kadel
- Genentech
- Nicole Baldwin
- Baylor Institute for Immunology Research
- Suchit Jhunjhunwala
- Genentech
- Dorothee Nickles
- Genentech
- Zoe June Assaf
- Genentech
- Daniel Bower
- Genentech
- Namrata Patil
- Genentech
- Mark McCleland
- Genentech
- David Shames
- Genentech
- Luciana Molinero
- Genentech
- Mahrukh Huseni
- Genentech
- Shomyseh Sanjabi
- Genentech
- Craig Cummings
- Genentech
- Ira Mellman
- Genentech
- Sanjeev Mariathasan
- Genentech
- Priti Hegde
- Foundation Medicine
- Thomas Powles
- Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London
- DOI
- https://doi.org/10.1038/s41467-021-24112-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
PD-L1 immune checkpoint inhibition has been used for several tumour types. Here, the authors use immunohistochemistry, tumour mutation burden and RNA-seq data from 366 patients with different indications to identify molecular signatures of response to atezolizumab and reveal pathway heterogeneity and the involvement of non-immune pathways.
